Copyright © Inderes 2011 - present. All rights reserved.
  • Senaste
  • Börs
    • Aktiejämförelse
    • Börskalender
    • Utdelningskalender
    • Aktieanalys
    • Artiklar
  • inderesTV
  • Portfölj
  • Forum
  • Q&A
  • Om oss
    • Följda bolag
    • Teamet
Regulatoriskt pressmeddelande

Report from Annual General Meeting of Vitrolife AB (publ)

Vitrolife
Ladda ner börsmeddelandet

At the Annual General Meeting of Vitrolife AB today, the following, amongst other things, was decided:

  • Resolution in accordance with the Board's proposed dividend of SEK 1.10 per share for the financial year 2024. 2 May, 2025 was adopted as the record day.
  • Re-election of Board members Henrik Blomquist, Lars Holmqvist, Pia Marions, Jón Sigurdsson and Karen Lykke Sørensen, in accordance with the election committee's proposal. Jón Sigurdsson was elected Chairman of the Board.
  • Remuneration to the Board members is proposed to be in total SEK 3 670 000 (3 300 000) of which SEK 1 350 000 (1 200 000) to the Chairman of the Board, SEK 450 000 (400 000) to each of the other members of the Board, SEK 160 000 (150 000) to the Chairman of the Audit Committee and SEK 80 000 (75 000) to each of the other members of the Audit Committee. 
  • The Election Committee proposes re-election of the auditor Deloitte AB and with unchanged remuneration principles.
  • Authorization for the Board, for the time up until the next Annual General Meeting and on one or more occasions, to resolve to issue a maximum of 13,544,719 shares in total, corresponding to just below 10 percent of the company's share capital. 
  • Authorization for the Board, for the time up until the next Annual General Meeting and on one or more occasions, to resolve on acquisition of the company's own shares. The Company can at no time hold more than 10 percent of the total shares in the Company. 
  • The proposed guidelines for remuneration and other conditions of employment for the executive management team were approved.
  • Resolution to entering a share swap agreement in order to secure delivery of shares to participants in LTIP 2025 and the potential financial impacts of LTIP 2025.
     

Gothenburg, April 29, 2025
VITROLIFE AB (publ)
The Board

 

The information was submitted for publication, through the agency of the contact persons set out above, at "Innehållet inom klamrarna kommer ersättas med rätt tid och datum vid utskickstillfället">"Innehållet inom klamrarna kommer ersättas med rätt tid och datum vid utskickstillfället">29-04-2025 16:56 CET.

Följ oss på våra kanaler i social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Ta kontakt
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • Om oss
  • Teamet
  • Jobba hos oss
  • Inderes som en investering
  • Tjänster för börsbolag
Vår plattform
  • FAQ
  • Servicevillkor
  • Integritetspolicy
  • Disclaimer
Inderes disclaimer gällande utförda aktieanalyser kan läsas här. För mer detaljerad information över de aktier som aktivt bevakas av Inderes, vänligen se respektive bolags bolagsspecifika sida på Inderes webbplats. © Inderes Oyj. Alla rättigheter förbehållna.